Itchiness around injection site; Hardness around injection site; Swelling around injection site; Redness around injection site; Pain and tnderness around injection site; tenderness around injection site; Injection site warm to touch; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (tenderness around injection site), VACCINATION SITE WARMTH (Injection site warm to touch), VACCINATION SITE PRURITUS (Itchiness around injection site), VACCINATION SITE INDURATION (Hardness around injection site) and VACCINATION SITE SWELLING (Swelling around injection site) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Fibromyalgia in 1995, Osteoarthritis, Irritable bowel syndrome in 1996, Overactive bladder in 1981, Mitral valve prolapse in 1991 and Acid reflux (esophageal) in 1996. Concurrent medical conditions included Drug allergy (Patient is allergic to Sulfa drugs,Aspartame and Nyquil /Dayquil) and Penicillin allergy. Concomitant products included OMEPRAZOLE for Acid reflux (esophageal), CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) for Allergy, VITAMIN D3 for Deficiency vitamin, CURCUMA LONGA RHIZOME (TURMERIC CURCUMIN [CURCUMA LONGA RHIZOME]) for Fibromyalgia, FISH OIL (OMEGA 3 FISH OILS) and ALLIUM SATIVUM (GARLIC NATURAL) for Heart disease, unspecified, CALCIUM CARBONATE (CALTRATE [CALCIUM CARBONATE]) for Osteopenia, OXYBUTYNIN for Overactive bladder, CALCIUM and BIOTIN for an unknown indication.    On 13-Feb-2021 at 9:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, the patient experienced TENDERNESS (tenderness around injection site), VACCINATION SITE ERYTHEMA (Redness around injection site) and VACCINATION SITE PAIN (Pain and tnderness around injection site). 13-Feb-2021, the patient experienced VACCINATION SITE WARMTH (Injection site warm to touch). On 13-Feb-2021 at 12:00 PM, the patient experienced VACCINATION SITE SWELLING (Swelling around injection site). On 25-Feb-2021, the patient experienced VACCINATION SITE INDURATION (Hardness around injection site). On 25-Feb-2021 at 8:00 AM, the patient experienced VACCINATION SITE PRURITUS (Itchiness around injection site). On 16-Feb-2021, TENDERNESS (tenderness around injection site), VACCINATION SITE WARMTH (Injection site warm to touch), VACCINATION SITE SWELLING (Swelling around injection site), VACCINATION SITE ERYTHEMA (Redness around injection site) and VACCINATION SITE PAIN (Pain and tnderness around injection site) had resolved. On 28-Feb-2021, VACCINATION SITE PRURITUS (Itchiness around injection site) and VACCINATION SITE INDURATION (Hardness around injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Between 13-Feb-2021 to 15-Feb-2021, Patient experienced swelling, redness, pain, itchiness, and hardness around injection site. The symptoms returned on 25-Feb-2021. Patient did not received treatment for the symptoms.   This case was linked to MOD-2021-099673 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: Follow up received .Medical history, concomitant medication information updated. On 05-May-2021: Follow up received and no new information was provided. On 30-May-2021: Followup received and no new information was added.